NCT03702660

Effect of GIP After a Meal in Patients With Type 2 Diabetes

Effect of GIP-receptorantantagonist on Glucagon Plasma Levels After a Meal in Patients With Type 2-diabetes

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University Hospital, Gentofte, Copenhagen · Academic / Other
• Sex: Male
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to investigate the effects of antagonising GIP after a meal on plasma levels of glucagon. 10 participants are going through four experimental days each, where they ingest a meal and afterwards receive infusions of either GIP receptor antagonist, GLP-1, GIP receptor antagonist + GLP-1 or placebo (saline) in a randomised order. The primary endpoint of the study is plasma levels of glucagon, which we hypothesize will decrease with infusion of GIP receptor antagonist and/or with infusion of GLP-1.

Conditions

• Type2 Diabetes

Interventions

Type	Name	Description
OTHER	GIP(3-30)NH2	Peptide derived from the naturally occuring gut hormone GIP
OTHER	Peripheral venous cannulation	Intravenous access for infusions
OTHER	GLP-1	Peptide infusion

Timeline

• Start date: 2017-08-01
• Primary completion: 2018-01-23
• Completion: 2018-01-23
• First posted: 2018-10-11
• Last updated: 2021-04-27

Locations

1 site across 1 country: Denmark